Home
/
Kymera Therapeutics, Inc.
/
Financials
/
Quarterly
Kymera Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Kymera Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.76M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$11.48M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$22.10M
May 9, 2025
Q3
2025
Sep 30, 2024
$3.74M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$25.65M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$10.29M
May 9, 2025
Q3
2024
Sep 30, 2023
$4.73M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$16.51M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$9.47M
May 2, 2024
Q3
2023
Sep 30, 2022
$9.55M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$11.51M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$9.62M
May 4, 2023
Q3
2022
Sep 30, 2021
$20.34M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$18.52M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$18.70M
May 3, 2022
Q3
2021
Sep 30, 2020
$14.53M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$3.29M
Aug 6, 2021
Q1
2021
Mar 31, 2020
$3.43M
May 6, 2021
Q3
2020
Sep 30, 2019
$950.0K
Nov 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($82.18M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($76.61M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($65.58M)
May 9, 2025
Q3
2025
Sep 30, 2024
($62.49M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($42.06M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($48.56M)
May 9, 2025
Q3
2024
Sep 30, 2023
($52.87M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($38.80M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($40.93M)
May 2, 2024
Q3
2023
Sep 30, 2022
($43.00M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($40.26M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($36.68M)
May 4, 2023
Q3
2022
Sep 30, 2021
($28.58M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($24.66M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($13.08M)
May 3, 2022
Q3
2021
Sep 30, 2020
($7.99M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($13.99M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($10.93M)
May 6, 2021
Q3
2020
Sep 30, 2019
($11.42M)
Nov 5, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($92.52M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($84.56M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($74.43M)
May 9, 2025
Q3
2025
Sep 30, 2024
($72.12M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($50.93M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($57.83M)
May 9, 2025
Q3
2024
Sep 30, 2023
($57.51M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($43.38M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($45.33M)
May 2, 2024
Q3
2023
Sep 30, 2022
($44.88M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($40.81M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($36.93M)
May 4, 2023
Q3
2022
Sep 30, 2021
($28.64M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($24.73M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($13.17M)
May 3, 2022
Q3
2021
Sep 30, 2020
($8.08M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($14.19M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($11.25M)
May 6, 2021
Q3
2020
Sep 30, 2019
($11.86M)
Nov 5, 2020